Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001582 · ClinicalTrials.gov registry record
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 902
- Enrollment target
NCT00001582: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001582 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 902 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001582 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 902 participants
- Enrollment target
Study Summary
This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol. The purpose of this study is to examine the factors involved in the regulation of the immune system of healthy individuals and to define the abnormalities in this regulation that underlies the immunological disorders of patients with a variety of immunodeficiency and malignant disorders. The studies will include the ex vivo phenotypic and functional analysis of the network of cells involved in humoral and cellular immune responses, and in vivo testing for the capacity to make delayed-type hypersensitivity and humoral responses following immunization with a variety of antigens. Individuals to be studied will include patients with a variety of malignancies and patients with primary and secondary immunodeficiency disorders. Selected family members or family members known to be genetic carriers of certain immunodeficiency diseases as well as normal, unrelated individuals will also be studied. A small number of procedures will be used including analysis of blood obtained by phlebotomy, apheresis, skin testing and recall antigens and immunization to assess humoral immunity....
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 902 participants |
| Start Date | 1997-06-07 |
| Est. Completion | 2023-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001582
The ClinicalTrials.gov registry entry for NCT00001582 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001582 about?
NCT00001582 is a clinical study titled "Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer". This protocol is being submitted to consolidate, update, and expand two previously approved protocols (77-C-0066 and 82-C-0044) into a single protocol. The purpose of this study is to examine the factors involved in the regulation of the immune system of healthy individuals and to define the abnorma...
What is the current status of trial NCT00001582?
This trial is currently completed. The enrollment target is 902 participants. The study started on 1997-06-07. Estimated completion is 2023-03-17.
Who is sponsoring clinical trial NCT00001582?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.